Biosensors International Group announced today that it has received CE Mark approval for both 33mm and 36mm lengths of its BioMatrix Flex drug-eluting stent (DES) system, further expanding the currently available range of 8mm to 28mm lengths. Both longer lengths of stent are available in diameters ranging from 2.50mm to 3.50mm.

These new additions to the BioMatrix Flex portfolio offer a significant opportunity to increase market penetration, as an estimated 15% of all DES usage involves long lengths.

“We have been very encouraged by the uptake of our latest addition to the BioMatrix stent family since its launch in May of this year”, commented President and CEO Jeffrey B. Jump. “We anticipate that the availability of BioMatrix Flex in these longer lengths will further enhance our penetration of the global DES market”.

The BioMatrix Flex drug-eluting stent received CE Mark approval in January 2010 and is currently available in major European, Middle East and African markets, as well as in selected Asian markets.

The BioMatrix Flex stent combines Biosensors’ unique biodegradable polymer technology with an improved mechanical platform for enhanced deliverability.